WuXi PharmaTech Leads $15 Million Investment in Claritas Genomics

WuXi NextCODE Genomics, the newly formed genomic analysis division of WuXi PharmaTech led a $15 million Series B financing in Claritas Genomics. Claritas is a Boston-based lab that develops and provides next-gen sequence-based tests for pediatric genomic disorders. The company was spun out of Boston Children’s Hospital two years ago with assistance from Life Technologies. WuXi NextCODE was formed earlier this year when WuXi PharmaTech paid $65 million to acquire NextCODE Health, a genomics sequencing company. More details.... Stock Symbols: (NYSE: WX) (NSDQ: LIFE) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.